Lactosylated IR820/DOX Co-Assembled Nanodrug for Synergetic Antitumour Therapy

Yue Jiang,1 Chunzhi Huang,1,2 Yuxia Luan1 1Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong Province, People’s Republic of China; 2Department of Pharmacy, Third Affiliated Hospit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jiang Y, Huang C, Luan Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	excipient-free hepatoma cell targeting self-assembly nanodrug photothermal therapy chemotherapy Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/f698efbba04c403593f6b74b0a6fee32
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f698efbba04c403593f6b74b0a6fee32
record_format	dspace
spelling	oai:doaj.org-article:f698efbba04c403593f6b74b0a6fee322021-12-02T10:06:28ZLactosylated IR820/DOX Co-Assembled Nanodrug for Synergetic Antitumour Therapy1178-2013https://doaj.org/article/f698efbba04c403593f6b74b0a6fee322020-06-01T00:00:00Zhttps://www.dovepress.com/lactosylated-ir820dox-co-assembled-nanodrug-for-synergetic-antitumour--peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Yue Jiang,1 Chunzhi Huang,1,2 Yuxia Luan1 1Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong Province, People’s Republic of China; 2Department of Pharmacy, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, People’s Republic of ChinaCorrespondence: Yuxia LuanDepartment of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 Wenhuaxi Road, Jinan, Shandong Province 250012, People’s Republic of ChinaTel +86 531-88382007Fax +86 531-88382548Email yuxialuan@sdu.edu.cnIntroduction: Synergistic treatment integrating photothermal therapy (PTT) and chemotherapy is a promising strategy for hepatocellular carcinoma (HCC). However, the most commonly used photothermal agent, IR820, and chemotherapeutic drug, doxorubicin hydrochloride (DOX), are both hydrophilic molecules that suffer from the drawbacks of a short circulation time, rapid elimination and off-target effects.Methods and Results: Herein, a novel nanodrug that combined HCC-targeted IR820 and DOX was developed based on excipient-free co-assembly. First, lactosylated IR820 (LA-IR820) was designed to target HCC. Then, the LA-IR820/DOX nanodrug (LA-IR820/DOX ND) was purely self-assembled without excipient assistance. The physicochemical properties and the chemo-photothermal antitumour activity of the excipient-free LA-IR820/DOX ND were evaluated. More importantly, the obtained LA-IR820/DOX ND exhibited 100% drug loading, remarkable HCC targeting and excellent antitumour efficacy.Conclusion: This excipient-free LA-IR820/DOX ND may be a promising candidate for the synchronous delivery and synergistic targeting of IR820 and DOX as a combined chemo-photothermal therapy.Keywords: excipient-free, hepatoma cell targeting, self-assembly nanodrug, photothermal therapy, chemotherapyJiang YHuang CLuan YDove Medical Pressarticleexcipient-freehepatoma cell targetingself-assembly nanodrugphotothermal therapychemotherapyMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 15, Pp 4431-4440 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	excipient-free hepatoma cell targeting self-assembly nanodrug photothermal therapy chemotherapy Medicine (General) R5-920
spellingShingle	excipient-free hepatoma cell targeting self-assembly nanodrug photothermal therapy chemotherapy Medicine (General) R5-920 Jiang Y Huang C Luan Y Lactosylated IR820/DOX Co-Assembled Nanodrug for Synergetic Antitumour Therapy
description	Yue Jiang,1 Chunzhi Huang,1,2 Yuxia Luan1 1Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong Province, People’s Republic of China; 2Department of Pharmacy, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, People’s Republic of ChinaCorrespondence: Yuxia LuanDepartment of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 Wenhuaxi Road, Jinan, Shandong Province 250012, People’s Republic of ChinaTel +86 531-88382007Fax +86 531-88382548Email yuxialuan@sdu.edu.cnIntroduction: Synergistic treatment integrating photothermal therapy (PTT) and chemotherapy is a promising strategy for hepatocellular carcinoma (HCC). However, the most commonly used photothermal agent, IR820, and chemotherapeutic drug, doxorubicin hydrochloride (DOX), are both hydrophilic molecules that suffer from the drawbacks of a short circulation time, rapid elimination and off-target effects.Methods and Results: Herein, a novel nanodrug that combined HCC-targeted IR820 and DOX was developed based on excipient-free co-assembly. First, lactosylated IR820 (LA-IR820) was designed to target HCC. Then, the LA-IR820/DOX nanodrug (LA-IR820/DOX ND) was purely self-assembled without excipient assistance. The physicochemical properties and the chemo-photothermal antitumour activity of the excipient-free LA-IR820/DOX ND were evaluated. More importantly, the obtained LA-IR820/DOX ND exhibited 100% drug loading, remarkable HCC targeting and excellent antitumour efficacy.Conclusion: This excipient-free LA-IR820/DOX ND may be a promising candidate for the synchronous delivery and synergistic targeting of IR820 and DOX as a combined chemo-photothermal therapy.Keywords: excipient-free, hepatoma cell targeting, self-assembly nanodrug, photothermal therapy, chemotherapy
format	article
author	Jiang Y Huang C Luan Y
author_facet	Jiang Y Huang C Luan Y
author_sort	Jiang Y
title	Lactosylated IR820/DOX Co-Assembled Nanodrug for Synergetic Antitumour Therapy
title_short	Lactosylated IR820/DOX Co-Assembled Nanodrug for Synergetic Antitumour Therapy
title_full	Lactosylated IR820/DOX Co-Assembled Nanodrug for Synergetic Antitumour Therapy
title_fullStr	Lactosylated IR820/DOX Co-Assembled Nanodrug for Synergetic Antitumour Therapy
title_full_unstemmed	Lactosylated IR820/DOX Co-Assembled Nanodrug for Synergetic Antitumour Therapy
title_sort	lactosylated ir820/dox co-assembled nanodrug for synergetic antitumour therapy
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/f698efbba04c403593f6b74b0a6fee32
work_keys_str_mv	AT jiangy lactosylatedir820doxcoassemblednanodrugforsynergeticantitumourtherapy AT huangc lactosylatedir820doxcoassemblednanodrugforsynergeticantitumourtherapy AT luany lactosylatedir820doxcoassemblednanodrugforsynergeticantitumourtherapy
_version_	1718397682366545920

Lactosylated IR820/DOX Co-Assembled Nanodrug for Synergetic Antitumour Therapy

Ejemplares similares